PANXEON blood test finds 87% of early pancreatic cancers in Nature Medicine study

A blood assay called PANXEON detected most early pancreatic cancers in a prospective study published in Nature Medicine on 16 September 2026. Combined with the existing marker CA19-9, it identified 86.8 percent of stage I and II pancreatic ductal adenocarcinoma in the testing cohort. The false-positive rate was 3.2 percent among low-risk controls and 15.6 percent among high-risk controls.

PANXEON stands for PANcreatic cancer eXosome Early detectiON. Senior author Ajay Goel, who chairs molecular diagnostics and experimental therapeutics at City of Hope in Duarte, California, has argued that the useful result is not a slogan about screening the public. It is a way to decide which already high-risk patients should go on to imaging.

The study enrolled 1,785 people with and without pancreatic cancer in four countries. Popular write-ups rounded that figure to about 1,800 and placed sites in the United States, Europe and Asia. The paper itself is titled “Liquid biopsy for early detection of pancreatic ductal adenocarcinoma.”

What the test actually measures

PANXEON does not look for a single molecule. It measures circulating microRNAs, exosomal microRNAs and CA19-9, then folds those readings into one score. The microRNA panel listed in the abstract includes hsa-miR-142-3p, hsa-miR-30c-5p, hsa-miR-335-5p, hsa-miR-340-5p, hsa-miR-200b-3p, hsa-miR-1260b, hsa-miR-145-3p, hsa-miR-145-5p, hsa-miR-429 and hsa-miR-200a-3p.

On its own, the microRNA signature produced an area under the receiver operating characteristic curve of 88.6 percent in the testing cohort and 83.8 percent sensitivity for early-stage disease. Cross-reaction with other gastrointestinal cancers was described as minimal. Adding CA19-9 lifted sensitivity for stage I–II cancer to 86.8 percent.

A smaller group of 19 patients offered a different kind of check. Signature levels fell during neoadjuvant chemotherapy and after surgery, then rose before recurrence. That pattern is what you want from a marker that is tracking tumour burden rather than some unrelated blood change.

The dysplasia finding

The result that changes clinical conversation is not only the 87 percent figure on early invasive cancer. PANXEON also flagged high-grade dysplasia in 64.3 percent of people who already had high-risk pancreatic cysts. High-grade dysplasia is the last step before invasion. Many of those cysts are watched for years because surgeons do not want to remove a pancreas on a weak signal.

The microRNA component, not CA19-9, appeared to carry most of that pre-invasive signal. The test stayed negative in 75.5 percent of cysts that did not have high-grade dysplasia. If those numbers hold in a larger cyst-surveillance cohort, gastroenterologists would have a blood step between a worrying scan and an operation.

Goel’s public comments have stayed inside that frame. The assay is not a replacement for CT, MRI or endoscopic ultrasound. It is a filter for people with inherited risk, prior pancreatitis or known cysts.

Why pancreatic cancer needs a filter

Most pancreatic ductal adenocarcinoma is found after it has left the pancreas. Five-year survival collapses once that happens. CA19-9, the marker already in clinics, misses too many early cases and rises in other conditions. A three-marker score with an 88.6 percent AUROC is still a research result. It is also the first liquid biopsy in this disease that has been run at this scale with a pre-invasive readout attached.

The paper ends where it should. The authors say PANXEON “warrants further large-scale prospective studies.” That is the next cost. A surveillance trial in high-risk clinics will decide whether 3.2 percent false positives in low-risk blood, and 15.6 percent in high-risk blood, are tolerable when the follow-up test is a scan rather than a needle.

Until that trial reports, the 16 September paper is a measurement, not a product launch. The measurement is specific. In 1,785 people, a microRNA-plus-CA19-9 score caught most stage I and II pancreatic cancers and more than three in five high-grade cyst lesions.